Regulatory Updates
Sep 8, 2026•1 min read
Samjin and Jongkundang Voluntarily Cut Prices of Epilepsy and Ezetimibe Drugs
Samjin’s third‑generation epilepsy drug Brivaracetam and Jongkundang’s ezetimibe combo LypiroUjet will have reduced insurance prices from next month, with cuts ranging 3‑11%.
Regulatory Updates
Sep 8, 2026•1 min read
KPA Forms Emergency Committee to Counter Expanded Telemedicine Prescription Delivery Policy
The Korean Pharmaceutical Association establishes an emergency response committee to address the government’s plan to broaden delivery of prescription drugs for telemedicine patients.
2
Regulatory Updates
Sep 7, 2026•1 min read
MFDS Expands Controlled Substance Monitoring to Include Propofol
South Korea's MFDS will extend its medical narcotics prescription monitoring system to cover the anesthetic propofol, with checks advisory and alerts for high‑frequency use.
Regulatory Updates
Sep 7, 2026•1 min read
South Korea Strengthens On‑Site Monitoring of Medical Narcotics with New Training Program
MFDS, Korea Pharmaceutical Safety Management Agency and Seoul city will hold a medical narcotics safety management training for Seoul’s monitoring officials on March 28.
Regulatory Updates
Sep 7, 2026•1 min read
South Korean Lawmaker Proposes Mandatory Psychiatric Care for Inmates with Mental Health Risks
Lawmaker Seo Young-seok introduced a bill to require psychiatric evaluation for inmates suspected of mental illness or self‑harm risk, noting inmate numbers have doubled since 2016.
Regulatory Updates
Sep 7, 2026•1 min read
MFDS reveals illegal distribution of unapproved foreign medicines in Korean import markets
A joint inspection of 10 import shopping centers uncovered unapproved Japanese and US medicines, including pain relievers, cold drugs, gastrointestinal meds, and psychoactive substances, sold without approval.
Regulatory Updates
Sep 7, 2026•1 min read
Amgen Korea’s Blincyto Gains Health‑Insurance Coverage for Ph‑Negative B‑Cell ALL in Sep 2024
From September, Blincyto (blinatumomab) will be reimbursed for Ph‑negative CD19‑positive precursor B‑cell ALL patients aged ≥1 year who achieve MRD‑negative remission.
Regulatory Updates
Sep 7, 2026•1 min read
Korea health authorities guide duplicate‑prescription claims for disaster‑area patients
The Ministry of Health and Welfare and HIRA issued instructions for residents of Geoje and Tongyeong special disaster zones to cite a ‘C/’ reason when claiming medical benefits for re‑prescribed medicines lost in heavy rain.
1
Regulatory Updates
Sep 7, 2026•1 min read
Six RSA‑covered Oncology Drugs See Contract Changes and Renewals in Korea
Next month, six RSA‑linked medicines—including Tisentric, Opdivo and Blincyto—will have contract terms revised, while six others such as Linparza and Opdivo enter re‑contracting as their RSA periods expire.
1
Regulatory Updates
Sep 7, 2026•1 min read
Seoul Pharmacists Association Calls for Prompt Review of Pending Pharmacy Legislation
The Seoul City Pharmacists Association asked the National Assembly to expedite review and enactment of pending pharmacist‑related bills, delivering a legislative urging letter to lawmaker Jeon Hyun‑hee.
Regulatory Updates
Sep 7, 2026•1 min read
Korean Parliament Passes Pharmacy Naming Restriction Law
The National Assembly approved the 'Pharmacy Naming Restriction Law' aimed at preventing misleading pharmacy titles that could treat medicines as consumer goods.
1
Regulatory Updates
Sep 7, 2026•1 min read
National Bio Innovation Committee Urges Integrated Regulatory and Investment Reform at CPHI Korea 2026
At CPHI Korea 2026, committee member Seo Kyung‑won urged Korea to abandon fragmented ministries and redesign its regulatory and investment ecosystem to become a global bio‑health leader.